TY - T1的调查之间的关系碱受体酪氨酸激酶抑制剂和肺动脉高血压:比例失调的分析从世界卫生组织药物警戒数据库JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01576 -2021欧元SP - 2101576 AU -查尔斯艺AU -亚历克斯Hlavaty盟-马修Roustit AU -让-吕克·Cracowski盟Marie-Camille Chaumais AU -马克·亨伯特AU -大卫Montani Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/09/13993003.01576 2021. -抽象N2 - Awada和他的同事们最近发表在《欧洲呼吸杂志》上一个有趣的临床前研究表明crizotinib可能加重,使肺动脉高血压(PAH) [1]。Crizotinib是first-in-class未分化淋巴细胞激酶抑制剂(碱性),现在是一个标准的一线治疗先进ALK-positive非小细胞肺癌(NSCLC) [2]。不一致的功效和能力有限控制脑转移推动发展的第二代筛选酪氨酸激酶抑制剂(TKI) (ceritinib, alectinib和brigatinib)的特点是高选择性和分发给中枢神经系统。此外,第三代ALK-TKI如lorlatinib或entrectinib最近发展克服由于二次筛选获得性耐药突变,担心超过一半的患者的第二代ALK-TKI [3]。PAH病例发病也报告发生了转移性非小细胞肺癌患者接受等ALK-TKI brigatinib和lorlatinib (4、5)。随后,你可以问问这副反应是特定于crizotinib或类ALK-TKI效应,以及目标和非目标酪氨酸激酶是否涉及其病理生理学。进一步增加知识这种潜在的药物不良反应(ADR),我们旨在全面描述PAH ALK-TKI使用,使用那些药物警戒数据库描述病例临床特征和评估其因果关系。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。请打开或下载PDF查看这篇文章。Conflict of Interest: Charles Khouri has nothing to disclose.Conflict of Interest: Alex Hlavaty has nothing to disclose.Conflict of Interest: Matthieu Roustit reports grants to institution (Grenoble University Hospital) for a clinical research on diabetic foot ulcers from United Therapeutics; patent for Grenoble University PCT/EP2014/065093, device using treprostinil (Remodulin®) to treat cutaneous ulcers; outside the submitted work.Conflict of Interest: Jean-Luc Cracowski has nothing to disclose.Conflict of Interest: Marie-Camille Chaumais has nothing to disclose.Conflict of Interest: Marc Humbert reports grants paid to institution, consulting fees for steering committee, speaker fees, and advisory board membership from Acceleron, Janssen, Merck; speaker fees from AOP; outside the submitted work.Conflict of Interest: David Montani reports grants paid to institution from Acceleron, Janssen, Merck; consulting fees for steering committee from Acceleron; speaker fees from Bayer, Janssen, Merck; outside the submitted work.Conflict of Interest: All other authors have nothing to disclose. ER -